GSK announced that Nucala (mepolizumab) has received approval in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP). This marks the third indication for mepolizumab in China, making it the only anti-interleukin-5 therapy approved for CRSwNP in the country. The treatment serves as an add-on therapy with intranasal corticosteroids for patients whose condition is not adequately controlled by systemic corticosteroids or surgery.The approval is based on the phase III MERIT trial results, which demonstrated significant improvements in nasal obstruction and quality of life measures over 52 weeks. The study, conducted across Japan, China, and Russia, showed consistent safety profiles with known mepolizumab data. The treatment offers a non-surgical alternative for approximately 30 million Chinese patients suffering from CRSwNP.CRSwNP affects about one-third of China's 107 million chronic sinusitis patients, causing symptoms like nasal obstruction, loss of smell, and sleep disturbance. Up to 80% of CRSwNP patients have type 2 inflammation, which Nucala specifically targets by inhibiting interleukin-5, a key inflammatory protein present in nasal polyp tissue.

GSK announced that Nucala (mepolizumab) has received approval in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP). This marks the third indication for mepolizumab in China, making it the only anti-interleukin-5 therapy approved for CRSwNP in the country. The treatment serves as an add-on therapy with intranasal corticosteroids for patients whose condition is not adequately controlled by systemic corticosteroids or surgery.The approval is based on the phase III MERIT trial results, which demonstrated significant improvements in nasal obstruction and quality of life measures over 52 weeks. The study, conducted across Japan, China, and Russia, showed consistent safety profiles with known mepolizumab data. The treatment offers a non-surgical alternative for approximately 30 million Chinese patients suffering from CRSwNP.CRSwNP affects about one-third of China's 107 million chronic sinusitis patients, causing symptoms like nasal obstruction, loss of smell, and sleep disturbance. Up to 80% of CRSwNP patients have type 2 inflammation, which Nucala specifically targets by inhibiting interleukin-5, a key inflammatory protein present in nasal polyp tissue.